ES2018367A6 - Un metodo para proporcionar variantes de t-pa humano. - Google Patents

Un metodo para proporcionar variantes de t-pa humano.

Info

Publication number
ES2018367A6
ES2018367A6 ES8901017A ES8901017A ES2018367A6 ES 2018367 A6 ES2018367 A6 ES 2018367A6 ES 8901017 A ES8901017 A ES 8901017A ES 8901017 A ES8901017 A ES 8901017A ES 2018367 A6 ES2018367 A6 ES 2018367A6
Authority
ES
Spain
Prior art keywords
variants
plasminogen activator
tissue plasminogen
processes
human tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8901017A
Other languages
English (en)
Inventor
Stephen P Anderson
Deborah L Higgins
Adair J Hotchkiss
Cara B Marks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Genetech Inc
Original Assignee
Genentech Inc
Genetech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22620139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2018367(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Genetech Inc filed Critical Genentech Inc
Publication of ES2018367A6 publication Critical patent/ES2018367A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Abstract

UN METODO PARA PROPORCIONAR VARIANTES DE T-PA HUMANO. EL METODO OBJETO DEL INVENTO SE CARACTERIZA PORQUE SE OBTIENE UNA VARIANTE DE T-PA QUE COMPRENDE T-PA MODIFICADO POR RETIRADA FUNCIONAL DE POR LOS MENOS UNA PORCION DE UN DOMINIO RESPONSABLE DE FIJACION A FIBRINA; SE MODIFICA ADICIONALMENTE LA VARIANTE DE T-PA DE ACUERDO CON LA OPERACION ANTERIOR PARA PRODUCIR UNA SEGUNDA VARIANTE DE T-PA; SE COMPARA LAS CARACTERISTICAS DE FIJACION A FIBRINA DE DICHA SEGUNDA VARIANTE DE T-PA A LA DE T-PA NATURAL; Y SE SELECCIONA UNA SEGUNDA VARIANTE DE T-PA ASI OBTENIDA, QUE EXHIBE FIJACION RESTAURADA A FIBRINA.
ES8901017A 1988-03-21 1989-03-21 Un metodo para proporcionar variantes de t-pa humano. Expired - Lifetime ES2018367A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/170,510 US5094953A (en) 1988-03-21 1988-03-21 Human tissue plasminogen activator variants

Publications (1)

Publication Number Publication Date
ES2018367A6 true ES2018367A6 (es) 1991-04-01

Family

ID=22620139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8901017A Expired - Lifetime ES2018367A6 (es) 1988-03-21 1989-03-21 Un metodo para proporcionar variantes de t-pa humano.

Country Status (13)

Country Link
US (4) US5094953A (es)
EP (1) EP0401303B2 (es)
JP (2) JP2605155B2 (es)
AT (1) ATE107960T1 (es)
AU (1) AU635892B2 (es)
CA (1) CA1341612C (es)
DE (1) DE68916532T3 (es)
DK (1) DK175776B1 (es)
ES (1) ES2018367A6 (es)
GR (1) GR1000387B (es)
IL (1) IL89500A (es)
NZ (1) NZ228401A (es)
WO (1) WO1989009266A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484L (fi) * 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
MX197183A (es) * 1982-05-05 1994-02-28 Genentech Inc Activador de plasminogeno de tejido humano
US5714372A (en) * 1985-04-22 1998-02-03 Genentech, Inc. Tissue plasminogen activator variants
KR970005046B1 (ko) * 1987-10-29 1997-04-11 야마노우찌 세이야꾸 가부시끼가이샤 개량형 조직 플라스미노겐 활성화 인자
DE3923339A1 (de) * 1989-05-31 1990-12-06 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator-derivat
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
ATE226642T1 (de) * 1994-07-07 2002-11-15 Tno Modifizierte proenzyme als substrate für proteolische enzyme
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
ATE313643T1 (de) * 1997-07-23 2006-01-15 Roche Diagnostics Gmbh Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination
US6136536A (en) * 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US6283300B1 (en) 1998-08-21 2001-09-04 Joseph B. Bielagus Feed distribution for low velocity air density separation
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
JP3880036B2 (ja) * 2001-05-11 2007-02-14 全国酪農業協同組合連合会 タンパク質の濃縮方法
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
EP1448127A1 (en) * 2001-11-06 2004-08-25 Maxim Pharmaceuticals, Inc. Compositions for the treatment of infectious diseases
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581652B1 (fr) * 1985-04-22 1989-12-22 Genentech Inc Nouveaux mutants de l'activateur tissulaire du plasminogene humain
EP0227462B1 (en) * 1985-12-23 1992-04-01 Chiron Corporation Novel peptide plasminogen activators
JP2527454B2 (ja) * 1986-01-31 1996-08-21 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新しい血栓溶解タンパク質
ATE70301T1 (de) * 1986-02-17 1991-12-15 Stichting Centraal Lab Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
PT84588B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it
EP0386240B1 (en) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Novel polypeptide compounds
DE3937589C2 (de) * 1989-11-10 2001-12-13 Laing Oliver Zirkulationsgerät mit Widerstandsheizung

Also Published As

Publication number Publication date
NZ228401A (en) 1991-09-25
US5366886A (en) 1994-11-22
US5314818A (en) 1994-05-24
DK227390D0 (da) 1990-09-20
AU635892B2 (en) 1993-04-08
EP0401303B2 (en) 1999-11-03
JP2605155B2 (ja) 1997-04-30
DE68916532T3 (de) 2000-02-03
EP0401303B1 (en) 1994-06-29
IL89500A0 (en) 1989-09-10
JPH03503363A (ja) 1991-08-01
AU3414889A (en) 1989-10-16
DK227390A (da) 1990-09-20
US5770425A (en) 1998-06-23
JPH09168387A (ja) 1997-06-30
US5094953A (en) 1992-03-10
GR890100164A (en) 1990-01-19
DK175776B1 (da) 2005-02-14
DE68916532D1 (de) 1994-08-04
EP0401303A1 (en) 1990-12-12
DE68916532T2 (de) 1995-01-12
CA1341612C (en) 2011-04-12
GR1000387B (el) 1992-06-30
ATE107960T1 (de) 1994-07-15
WO1989009266A1 (en) 1989-10-05
IL89500A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
IL89500A0 (en) Human tissue plasminogen activator variants and processes
FI943632A (fi) Kudosplasminogeeniaktivaattorin glykosylaatiomuunnelmat terapeuttisten ominaisuuksien parantamiseksi
DE69921102D1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
GR3033146T3 (en) Modified polypeptides with increased biological activity
IE831024L (en) Human tissue plasminogen activator
MY102472A (en) Preparation of funtional human urokinase proteins.
IL80659A (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
ES8602118A1 (es) Un procedimiento para preparar un conjugado de proteina fibrinoliticamente activa
AU2036188A (en) New tissue plasminogen activator
Sumi et al. Higher fibrin-binding and thrombolytic properties of single polypeptide chain-high molecular weight urokinase
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU1778988A (en) Novel fibrinolytic enzymes
EP0339505A3 (en) Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
ZA868813B (en) Dna sequence,recombinant dna and process for producing human tissue plasminogen activator

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20090323